News
07-27-2008, 09:41 PM
Amgen has announced findings from the pivotal fracture trial evaluating its RANK Ligand inhibitor, denosumab, in the treatment of postmenopausal osteoporosis.
More... (http://www.news-medical.net/?id=40271)
More... (http://www.news-medical.net/?id=40271)